Vyant Bio, Inc.

Good afternoon and welcome to the ViantBio first quarter 2022 earnings conference call and webcast. Today, May 16, 2022, the company issued a press release summarizing results for the first quarter 2022 and filed its form. Today's discussion will provide an overview of activities in the first quarter and 2022 is being recorded and a replay of the webcast will be available on the ViantBio website following today's call. Alternatively, the link can be sent to you by contacting ir at ViantBio.com. All participants on this call will be in a listen-only mode during the presentation. The presentation will be followed by a question and answer session. At this time, I would now like to turn the conference over to Jay Roberts, Chief Executive Officer of ViantBio. Please go ahead, sir.

Thank you, operator, and thank you all for joining the ViantBio Investor Conference call. and webcast for the first quarter of 2022. We're pleased to have a fresh start to the year for Buy and Bio, a new beginning in many ways. We spent the first quarter fully focused on progressing our scientific research and development business plan. Our call today will articulate some of the scientific insights that we have gained in the quarter, along with our financial results for the quarter. As such, on the call with me today is Buy and Bio's Chief Financial Officer, Andy LaFrance, and our Chief Scientific Officer, Dr. Robert Fermo. Following the safe harbor statement, I will start out describing the corporate initiatives we have accomplished so far this year. Then, Dr. Pervot will provide an overview and update on recent scientific achievements made in the quarter and the vision ahead. Finally, Andy LaFrance will take us through a brief financial update and discuss key accounting matters for the first quarter of 2022. I will make some closing remarks, and then we will open up the lines for questions. I will now turn the call over to our CFO, Andy LaFrance.

Thank you, Jay, and welcome to all. We would like to remind everyone that various comments about future expectations, plans, prospects, constitutes forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigations Reform Act of 1995. Bio cautions that these forward-looking statements are subject to risks and uncertainties They may cause our actual results to differ materially from those indicated, including risks described in the company's filings with the SEC. Any forward-looking statements made on this conference call speak only of today's date, Monday, May 16, 2022. Invite BioDesign 10 to update any of these forward-looking statements to reflect events or circumstances that would occur after today's date. This conference call is also being recorded for audio rebroadcast on Viant Bio's website at www.viantbio.com. With that, I would like to turn the call back over to Jay Roberts. Jay.